Arterial stiffening and systemic endothelial activation induced by smoking: The role of COX-1 and COX-2

International Journal of Cardiology

Volumn 189, Issue 1, 2015, Pages 293-298

  Vlachopoulos, Charalambos ^a   Aznaouridis, Konstantinos ^a   Bratsas, Athanassios ^a   Ioakeimidis, Nikolaos ^a   Dima, Ioanna ^a   Xaplanteris, Panagiotis ^a   Stefanadis, Christodoulos ^a   Tousoulis, Dimitris ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Arterial elasticity; Arterial stiffness; Cyclooxygenase; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; INTERLEUKIN 6; N(G),N(G) DIMETHYLARGININE; PLACEBO; CYCLOOXYGENASE 2 INHIBITOR;

ADULT; ANALYSIS OF VARIANCE; ARTERIAL STIFFNESS; ARTICLE; BODY MASS; CENTRIFUGATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ELASTICITY; ENDOTHELIUM; FEMALE; HEMODYNAMICS; HUMAN; MALE; NEWBORN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PULSE PRESSURE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SMOKING; SPHYGMOMANOMETRY; SYSTOLIC BLOOD PRESSURE; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; PATHOPHYSIOLOGY; REFERENCE VALUE; RISK ASSESSMENT; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ADULT; ANALYSIS OF VARIANCE; ASPIRIN; CARDIOVASCULAR DISEASES; CELECOXIB; CROSS-OVER STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; RISK ASSESSMENT; SMOKING; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 84929166951     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.04.029     Document Type: Article

References (41)

1. D.G. Yanbaeva, M.A. Dentener, E.C. Creutzberg, G. Wesseling, E.F. Wouters, Systemic effects of smoking, Chest 131 (2007) 1557-1566.
2. J.A. Ambrose, R.S. Barua, The pathophysiology of cigarette smoking and cardiovascular disease: an update, J. Am. Coll. Cardiol. 43 (2004) 1731-1737.
3. C. Vlachopoulos, K. Aznaouridis, C. Stefanadis, Clinical appraisal of arterial stiffness: the Argonauts in front of the Golden Fleece, Heart 92 (2006) 1544-1550.
4. A.A. Quyyumi, Prognostic value of endothelial function, Am. J. Cardiol. 91 (2003) 19H-24H.
5. S. Laurent, J. Cockcroft, L. Van Bortel, European Network for Non-invasive Investigation of Large Arteries, et al., Expert consensus document on arterial stiffness: methodological issues and clinical applications, Eur. Heart J. 27 (2006) 2588-2605.
6. E. Agabiti-Rosei, G. Mancia, M.F. O'Rourke, et al, Central blood pressure measurements and antihypertensive therapy: a consensus document, Hypertension 50 (2007) 154-160.
7. C. Vlachopoulos, K. Aznaouridis, C. Stefanadis, Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis, J. Am. Coll. Cardiol. 55 (2010) 1318-1327.
8. C. Vlachopoulos, K. Aznaouridis, M.F. O'Rourke, M.E. Safar, K. Baou, C. Stefanadis, Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis, Eur. Heart J. 31 (2010) 1865-1871.
9. K. Aznaouridis, C. Vlachopoulos, A. Protogerou, C. Stefanadis, Ambulatory systolic-diastolic pressure regression index as a predictor of clinical events. A meta-analysis of longitudinal studies, Stroke 43 (2012) 733-739.
10. C. Stefanadis, E. Tsiamis, C. Vlachopoulos, et al, Unfavorable effect of smoking on the elastic properties of the human aorta, Circulation 95 (1997) 31-38.
11. C. Vlachopoulos, F. Kosmopoulou, D. Panagiotakos, et al, Smoking and caffeine have a synergistic detrimental effect on aortic stiffness and wave reflections, J. Am. Coll. Cardiol. 44 (2004) 1911-1917.
12. D.S. Celermajer, K.E. Sorensen, D. Georgakopoulos, et al, Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium dependent dilatation in healthy young adults, Circulation 88 (1993) 2149-2155.
13. J. Lekakis, C. Papamichael, C. Vemmos, K. Stamatelopoulos, A. Voutsas, S. Stamatelopoulos, Effect of acute cigarette smoking on endothelium-dependent arterial dilatation in normal subjects, Am. J. Cardiol. 81 (1998) 1225-1228.
14. O.T. Raitakari, M.R. Adams, R.J. McCredie, K.A. Griffiths, D.S. Celermajer, Arterial endothelial dysfunction related to passive smoking is potentially reversible in healthy young adults, Ann. Intern. Med. 130 (1999) 578-581.
15. N.A. Jatoi, P. Jerrard-Dunne, J. Feely, A. Mahmud, Impact of smoking and smoking cessation on arterial stiffness and aortic wave reflection in hypertension, Hypertension 49 (2007) 981-985.
16. B.F. McAdam, D. Byrne, J.D. Morrow, J.A. Oates, Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers, Circulation 112 (2005) 1024-1029.
17. M. Hermann, H. Krum, F. Ruschitzka, To the heart of the matter: coxibs, smoking, and cardiovascular risk, Circulation 112 (2005) 941-945.
18. W.M. Loke, K.L.M. Sing, C.Y.J. Lee, et al, Cyclooxygenase-1 mediated platelet reactivity in young male smokers, Clin. Appl. Thromb. Hemost. 20 (2014) 371-377.
19. C. Stefanadis, C. Vlachopoulos, E. Tsiamis, et al, Unfavorable effects of passive smoking on aortic function in men, Ann. Intern. Med. 128 (1998) 426-434.
20. C. Papamichael, K. Karatzi, E. Karatzis, et al, Combined acute effects of red wine consumption and cigarette smoking on haemodynamics of young smokers, J. Hypertens. 24 (2006) 1287-1292.
21. K. Karatzi, C. Papamichael, E. Karatzis, et al, Acute smoke-induced endothelial dysfunction is more prolonged in smokers than in non-smokers, Int. J. Cardiol. 120 (2007) 404-406.
22. C. Vlachopoulos, I. Dima, K. Aznaouridis, et al, Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals, Circulation 112 (2005) 2193-2200.
23. L. Smeeth, S.L. Thomas, A.J. Hall, R. Hubbard, P. Farrington, P. Vallance, Risk of myo-cardial infarction and stroke after acute infection or vaccination, N. Engl. J. Med. 351 (2004) 2611-2618.
24. T.J. Anderson, A. Uehata, M.D. Gerhard, et al, Close relation of endothelial function in the human coronary and peripheral circulations, J. Am. Coll. Cardiol. 26 (1995) 1235-1241.
25. B. Williams, P.S. Lacy, S.M. Thom, CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee, et al., Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study, Circulation 113 (2006) 1213-1225.
26. J.S. Bennett, A. Daugherty, D. Herrington, P. Greenland, H. Roberts, K.A. Taubert, The use of nonsteroidal anti-inflammatory drugs (NSAIDs). A science advisory from the American Heart Association, Circulation 111 (2005) 1713-1716.
27. M. Hermann, F. Ruschitzka, Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs, Ann. Med. 39 (2007) 18-27.
28. S.E. Kimmel, J.A. Berlin, M. Reilly, et al, Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction, Ann. Intern. Med. 142 (2005) 157-164.
29. P. McGettigan, D. Henry, Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2, JAMA 296 (2006) 1633-1644.
30. W.Z. Zhang, K. Venardos, J. Chin-Dusting, D.M. Kaye, Adverse effects of cigarette smoke on NO bioavailability. Role of arginine metabolism and oxidative stress, Hypertension 48 (2006) 278-285.
31. I.B. Wilkinson, S.S. Franklin, J.R. Cockcroft, Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology, Hypertension 44 (2004) 112-116.
32. I. Ikonomidis, J. Lekakis, G. Vamvakou, F. Andreotti, P. Nihoyannopoulos, Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment, Am. Heart J. 149 (2005) 832-839.
33. K. Bhagat, P. Vallance, Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo, Circulation 96 (1997) 3042-3047.
34. R.K. Kharbanda, B. Walton, M. Allen, et al, Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin, Circulation 105 (2002) 2600-2604.
35. W. Qi, J.X. Wei, I. Dorairaj, R.P. Mahajan, V.G. Wilson, Evidence that a prostanoid produced by cyclo-oxygenase-2 enhances contractile responses of the porcine isolated coronary artery following exposure to lipopolysaccharide, Br. J. Anaesth. 98 (2007) 323-330.
36. J. Blanco-Rivero, V. Cachofeiro, V. Lahera, et al, Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats, Hypertension 46 (2005) 107-112.
37. J. Blanco-Rivero, I. Márquez-Rodas, F.E. Xavier, et al, Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetylcholine by altering the cyclooxygenase pathway, Cardiovasc. Res. 75 (2007) 398-407.
38. S.S. Barbieri, B.B. Weksler, Tobacco smoke cooperates with interleukin-1β to alter β-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo, FASEB J. 21 (2007) 1831-1843.
39. J. Toivanen, O. Ylikorkala, L. Viinikka, Effects of smoking and nicotine on human prostacyclin and thromboxane production in vivo and in vitro, Toxicol. Appl. Pharmacol. 82 (1986) 301-306.
40. S. Roy, Effects of smoking on prostacyclin formation and platelet aggregation in users of oral contraceptives, Am. J. Obstet. Gynecol. 180 (1999) S364-S368.
41. P. Borgdorff, M.L. Handoko, Y.Y. Wong, G.T. Tangelder, COX-2 inhibition by use of rofecoxib or high dose aspirin enhances ADP-induced platelet aggregation in fresh blood, Open Cardiovasc. Med. J. 4 (2010) 198-205.